Effect of cimetidine on hepatic cytochrome P450: evidence for formation of a metabolite-intermediate complex

M Levine and GD Bellward

Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver.

Cimetidine is an inhibitor of hepatic cytochrome P450 (CYP) in vivo and in vitro in both rats and humans. However, the concentrations of cimetidine required to inhibit drug metabolism in hepatic microsomes in vitro are 100-1000-fold higher than those associated with a similar degree of inhibition in vivo. Recently, we provided evidence indicating that cimetidine selectively inhibits CYP2C11 in the rat and that it acts by forming a metabolite-intermediate (MI) complex. To investigate this further, optical-difference spectroscopy was performed with the use of microsomes from uninduced and phenobarbital-induced male rats treated with cimetidine in vivo or, after a preincubation step, in vitro. In microsomes from uninduced rats treated with cimetidine in vivo or in vitro, a spectral peak at 428-430 nm was observed that was not dissociated by the addition of potassium ferricyanide. The spectral peak obtained with cimetidine in vitro was dependent on the presence of NADPH and on the concentration of cimetidine in the reaction mixture, indicating the presence of an MI complex. The magnitude of this complex was reduced in microsomes from phenobarbital induced rats that were administered cimetidine either in vivo or in vitro. The formation of the complex was also inhibited by preincubation of the microsomes with anti-rat CYP2C11 immunoglobulin. These results are consistent with the hypothesis that cimetidine inhibits CYP in vivo in the rat by forming an MI complex, largely with CYP2C11, and that this complex can be generated in vitro by incubating microsomes with cimetidine in the presence of NADPH.

Volume 23, Issue 12, pp. 1407-1411, 12/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				B. V. Karanam, C. J. Welch, V. G. Reddy, J. Chilenski, M. Biba, and S. Vincent Drug Metab. Dispos., October 1, 2004; 32(10): 1061 - 1068. [Abstract] [Full Text] [PDF]

				M. Madeira, M. Levine, T. K. H. Chang, A. Mirfazaelian, and G. D. Bellward The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab. Dispos., April 1, 2004; 32(4): 460 - 467. [Abstract] [Full Text] [PDF]

				K. Yamano, K. Yamamoto, M. Katashima, H. Kotaki, S. Takedomi, H. Matsuo, H. Ohtani, Y. Sawada, and T. Iga Prediction of Midazolam{---}cyp3a Inhibitors Interaction in the Human Liver from in Vivo/in Vitro Absorption, Distribution, and Metabolism Data Drug Metab. Dispos., April 1, 2001; 29(4): 443 - 452. [Abstract] [Full Text]

				M. Levine, E. Y. W. Law, S. M. Bandiera, T. K. H. Chang, and G. D. Bellward In Vivo Cimetidine Inhibits Hepatic CYP2C6 and CYP2C11 but Not CYP1A1 in Adult Male Rats, J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 493 - 499. [Abstract] [Full Text]